States withdraw coverage for weight loss medications

Boxes of the diabetes medication Ozempic sit on a pharmacy counter in Los Angeles, reflecting the growing use of drugs like Ozempic to combat obesity. As their popularity rises, more than a dozen U.S. states have begun covering these medications under Medicaid. However, fiscal pressures are causing several states to restrict or end access.

Amid tightening budgets and anticipated cuts under federal tax and spending legislation, states are reassessing Medicaid coverage for GLP-1 medications, which are used to aid weight loss. According to a survey by the Kaiser Family Foundation (KFF), 16 state Medicaid programs now cover GLP-1s for obesity treatment, up from 13 last year. Despite this increase, several states have announced plans to end or limit coverage.

Supporters, including doctors and patient advocates, argue that GLP-1 drugs could reduce long-term healthcare costs by preventing obesity-related conditions such as heart disease and diabetes. Yet many states report that current funding constraints make continued coverage untenable.

North Carolina ended Medicaid coverage for GLP-1s in October, citing insufficient state funds. California, New Hampshire, and South Carolina will terminate coverage starting January 1. Michigan plans to limit access to individuals classified as morbidly obese, while Pennsylvania, Rhode Island, and Wisconsin are considering new restrictions.

Elizabeth Williams, a senior policy manager at KFF, noted that interest in GLP-1 coverage has shifted due to budget challenges and high costs. After several years of revenue growth following the pandemic, states are now facing slower revenues, rising expenses, and fiscal uncertainty, Williams explained.

Federal policy changes have also influenced coverage. The Trump administration rescinded a Biden-era proposal that would have required Medicaid to pay for certain GLP-1 medications for obesity. Recently, agreements with drug manufacturers to lower prices for Medicaid, Medicare, and direct consumers were announced, but it remains unclear how much this will reduce state expenditures.

State health plans for employees are reevaluating coverage as well. North Carolina removed GLP-1 coverage for state workers, while West Virginia canceled a 1,000-person pilot program.

Originally developed for Type 2 diabetes and cardiovascular conditions, GLP-1 medications regulate blood sugar. They also reduce appetite, leading to significant weight loss. Prescriptions under Medicaid for these drugs increased from 755,300 in 2019 to 3.8 million in 2023, with associated spending rising from $597.3 million to $3.9 billion.

The number of non-diabetic patients starting GLP-1 therapy increased more than 700% between 2019 and 2023. Yet, despite price reductions to $500 or less per month for consumers, many patients cannot afford the medication without insurance coverage.

Medical professionals warn that ending coverage has immediate consequences. Dr. Jennifer McCauley of UNC Health stated that patients in North Carolina are regaining weight and experiencing worsening health outcomes after losing Medicaid access.

Critics of extensive GLP-1 coverage argue that long-term benefits are limited because patients often regain weight after discontinuing the drugs. Nonetheless, physicians stress that reducing obesitys downstream effects can ultimately lower healthcare costs and improve outcomes for vulnerable populations.

Some states are attempting to maintain partial coverage by tightening prescription eligibility. Michigan and Pennsylvania are exploring such measures, while Connecticut requires beneficiaries to try online weight-loss counseling before receiving a prescription.

North Dakota adopted a unique approach after state Medicaid coverage legislation failed. The state now mandates that insurers in its ACA marketplace cover GLP-1 medications for medically necessary weight loss. Officials believe this policy will not significantly affect premiums and allows coverage for those with legitimate medical needs.

North Dakota Deputy Insurance Commissioner John Arnold explained that the measure focuses on patients with medical necessity rather than general weight loss, aiming to reduce obesity-related comorbidities and long-term insurance costs. The policys financial impact will be evaluated over time.

Analysis: The Future of GLP-1 Medication Coverage Amid Financial Constraints

The growing use of GLP-1 medications, such as Ozempic, for weight loss and obesity treatment has seen a sharp rise, yet the fiscal realities faced by states are now beginning to limit access to these drugs. As highlighted by the Kaiser Family Foundation, the number of states covering GLP-1 medications under Medicaid increased in recent years, but budgetary constraints have prompted several states to scale back or completely end these benefits. North Carolina’s decision to end coverage in October and other states like California, New Hampshire, and South Carolina planning similar actions in January underscore the growing divide between healthcare needs and state budgets.

Supporters of GLP-1 medications, including healthcare professionals and patient advocates, argue that these drugs can provide long-term cost savings by preventing obesity-related conditions such as diabetes and heart disease. However, many states are finding it increasingly difficult to justify the continued expenditure, especially in the face of slower revenues and rising healthcare costs. The question now is whether the potential health benefits can outweigh the financial burden states are grappling with, particularly when Medicaid programs are already under strain.

While federal changes, such as agreements with drug manufacturers to reduce prices, might alleviate some of the cost pressures, the impact of these changes remains uncertain. In the interim, some states are exploring partial coverage measures, such as tightening eligibility or requiring patients to undergo alternative weight-loss treatments before receiving prescriptions. North Dakota’s innovative approach of mandating insurers to cover GLP-1s for medically necessary weight loss, however, could offer a viable middle ground, addressing both health concerns and cost containment.

The real challenge for states moving forward will be balancing the immediate fiscal constraints with the long-term healthcare savings that GLP-1 medications may offer. If access to these medications continues to shrink, the medical community fears that many individuals will face worsening health outcomes and rising healthcare costs down the line. The future of GLP-1 medication coverage will likely depend on finding a sustainable model that can integrate financial responsibility with the goal of improving public health.

Sources:

• States retreat from covering drugs for weight loss